LFA-1 antagonists - Mitsubishi Tanabe Pharma

Drug Profile

LFA-1 antagonists - Mitsubishi Tanabe Pharma

Alternative Names: LFA-451; LFA-819

Latest Information Update: 26 May 2010

Price : $50

At a glance

  • Originator Tanabe Seiyaku
  • Class
  • Mechanism of Action Lymphocyte function-associated antigen-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Autoimmune disorders; Transplant rejection

Most Recent Events

  • 26 May 2010 Discontinued - Preclinical for Transplant rejection in Japan (unspecified route)
  • 26 May 2010 Discontinued - Preclinical for Autoimmune disorders in Switzerland (unspecified route)
  • 26 May 2010 Discontinued - Preclinical for Autoimmune disorders in Austria (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top